ArticleSchizophrenia bulletin open2022
Patients' Experiences of Clozapine for Treatment-Resistant Schizophrenia: A Systematic Review.
Article in Schizophrenia bulletin open, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Clozapine prescribing in Germany: temporal trends and regional variations, 2012-2022.Schizophrenia (Heidelberg, Germany) · 2026Article
- Underprescription of Clozapine: A Narrative Review Regarding 'Clozaphobia'.Human psychopharmacology · 2026Review
- Adult psychiatrists' views on clozapine prescribing for schizophrenia in Germany-an online survey.Therapeutic advances in psychopharmacology · 2026Article
- Low awareness of clozapine-induced agranulocytosis in a mixed-method survey of 354 patients and carers.Schizophrenia (Heidelberg, Germany) · 2025Article
- A Call to Action for Starting Clozapine: Increasing Clozapine Use and Safety in a Post-REMS Era.Focus (American Psychiatric Publishing) · 2025Review
- The Safety of 12-Weekly Monitoring of Neutrophil Count in Long-Term Clozapine Patients.Acta psychiatrica Scandinavica · 2025Observational
- A Case Report of Clozapine-Induced Cardiomyopathy.Cureus · 2025Article
- Deep Learning-Assisted SERS for Therapeutic Drug Monitoring of Clozapine in Serum on Plasmonic Metasurfaces.Nano letters · 2025Article
- Article
- Identifying clinically relevant agranulocytosis in people registered on the UK clozapine Central Non-Rechallenge Database: retrospective cohort study.The British journal of psychiatry : the journal of mental science · 2024Article
- Multi-level barriers and facilitators to implementing evidence-based antipsychotics in the treatment of early-phase schizophrenia.Frontiers in health services · 2024Article
- Experience with and attitude toward clozapine use among patients receiving clozapine on long term and their caregivers.Indian journal of psychiatry · 2023Article
- Clinical impact of reducing the frequency of clozapine monitoring: controlled mirror-image cohort study.The British journal of psychiatry : the journal of mental science · 2023Article
- The lived experience of clozapine discontinuation in patients and carers following suspected clozapine-induced neutropenia.BMC psychiatry · 2023Article
- What are the barriers and facilitators of clozapine use in early psychosis? A survey of UK early intervention clinicians.Schizophrenia (Heidelberg, Germany) · 2023Article
- Clozapine haematological monitoring for neutropenia: a global perspective.Epidemiology and psychiatric sciences · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Clozapine is the most effective antipsychotic for patients with treatment-resistant schizophrenia (TRS), however, it remains widely under-utilized in clinical practice. To date, relatively little attention has been given to patients' experience of clozapine. By synthesizing the existing literature, we sought to determine the experiences of patients with TRS treated with clozapine. Methods: A systematic review was conducted on Embase, Medline, PsychInfo, and PubMed databases for studies from 1956 to 2021. English language studies and those based on adult patients prescribed clozapine for TRS were included. Results: Thirteen studies were included with a total of 1487 patients and a narrative synthesis was performed. Overall, most patients reported positive experiences of clozapine, with generally high levels of satisfaction, alongside symptom improvement and preference over previous medications. Negative experiences of clozapine were less common, but when mentioned, focused on blood tests and common side effects, including hypersalivation and weight gain. Conclusions: This is the first systematic review exploring patients' subjective experiences of clozapine for TRS. Findings suggest that patients generally have a favorable experience when being treated with clozapine. However, conclusions are limited by the risk of bias, particularly survivorship bias. High-quality longitudinal studies exploring patients' experiences of clozapine are indicated for the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.